Viking Therapeutics Inc (NAS:VKTX)
$ 58.88 2.65 (4.71%) Market Cap: 6.49 Bil Enterprise Value: 5.24 Bil PE Ratio: 0 PB Ratio: 6.95 GF Score: 38/100

Viking Therapeutics Inc at UBS Global Healthcare Conference (Virtual) Transcript

May 18, 2020 / 07:00PM GMT
Release Date Price: $7.13 (+0.42%)
Sriker Mohan Nadipuram
UBS Investment Bank, Research Division - Associate Director and Research & Analysis Associate

Hi, everyone. Thanks for joining day 1 of our UBS Global Healthcare Conference. My name is Sriker Nadipuram, and I'm an associate on the U.S. pharma SMID cap biotech team here at UBS under senior analyst, Navin Jacobs.

And with that, it's my pleasure to welcome Brian Lian, CEO of Viking Therapeutics, to present on his company. Brian, take it away.

Brian Lian
Viking Therapeutics, Inc. - President, CEO & Director

Great. Thanks very much, and thanks to UBS for the opportunity to present. We really appreciate it.

I'll be making some forward-looking statements during the presentation today. I would encourage anybody listening to this presentation or viewing the slides to refer to the Securities and Exchange website -- Securities and Exchange Commission website for the most current information on the company.

Moving to Slide 3. I'll take you through the Viking story today. So we're a San Diego-based company,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot